Treatment of cutaneous leishmaniasis in Colombia with dapsone [7]

Lancet

Volumn 351, Issue 9101, 1998, Pages 498-499

  Osorio, Lyda Elena ^a   Palacios, Ricardo ^b   Chica, Martha Elena ^b   Ochoa, María Teresa ^b  

^a Ctro Internacional de E   (Colombia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DAPSONE;

ANEMIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HUMAN; LETTER; METHEMOGLOBINEMIA; NAUSEA; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SKIN LEISHMANIASIS; VOMITING;

EID: 0032515597     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)78687-6     Document Type: Article

References (3)

1. 1 Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997; 24: 684-703.
2. 2 Dogra J. Dapsone in the treatment of cutaneous leishmaniasis. Int J Dermatol 1986; 25: 398-401.
3. 3 Dogra J. A double-blind study on the efficacy of oral dapsone in cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1991; 85: 212-13.